[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05881356":3,"trial-entities:NCT05881356":86,"trial-summary:NCT05881356":90},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":20,"study_type":21,"primary_purpose":15,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":27,"secondary_outcomes":34,"sex":35,"minimum_age":36,"maximum_age":15,"healthy_volunteers":37,"eligibility_criteria":38,"std_ages":48,"locations":51,"central_contacts":68,"overall_officials":71,"references":74,"see_also_links":85},"NCT05881356","91191727","Discovering Factors in the Clinical Study Journey of Patients With OCD","Understanding the Patient Perspective: An Observational Study on Experiences of OCD Clinical Trial Patients","UNKNOWN","2026-06","2023-05","2023-05-31","2024-06","Power Life Sciences Inc.","INDUSTRY",null,"This research aims to collect comprehensive data on the clinical trial experience of OCD patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully. Clinical trial participation often favors specific demographic groups, and limited research exists on the impact of trial attributes on participation. Therefore, this study aims to analyze data from various demographic groups and identify any recurring trends that could provide valuable insights for future OCD patients.",[18,19],"OCD","Obsessive-Compulsive Disorder",[18,19],"OBSERVATIONAL",[],{"count":24,"type":25},500,"ESTIMATED",[],[28,31],{"measure":29,"timeFrame":30},"Rate of participants who decide to enroll in a OCD clinical study.","3 months",{"measure":32,"timeFrame":33},"Number of OCD patients who remain in clinical trial until completion.","12 months",[],"ALL","18 Years",false,{"inclusion":39,"exclusion":43,"raw_text":47},[40,41,42],"Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.","Participant has a diagnosis of OCD.","Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.",[44,45,46],"Pregnant or lactating woman","Enrolled in another research study","Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial","Inclusion Criteria:\n\n* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.\n* Participant has a diagnosis of OCD.\n* Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* Enrolled in another research study\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial",[49,50],"ADULT","OLDER_ADULT",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"contacts":59,"geoPoint":65},"Power Life Sciences","RECRUITING","San Francisco","California","94107","United States",[60],{"name":61,"role":62,"phone":63,"email":64},"Michael B Gill","CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"lat":66,"lon":67},37.77493,-122.41942,[69],{"name":61,"role":62,"phone":63,"email":70},"bask@withpower.com",[72],{"name":61,"affiliation":13,"role":73},"STUDY_DIRECTOR",[75,79,82],{"pmid":76,"type":77,"citation":78},"28384832","BACKGROUND","Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017 Apr 4;317(13):1358-1367. doi: 10.1001\u002Fjama.2017.2200.",{"pmid":80,"type":77,"citation":81},"29278206","Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy. Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174\u002F0929867325666171222163645.",{"pmid":83,"type":77,"citation":84},"963971","Bidlack JM, Lockshin RA. Evolution of LDH isozymes during programmed cell death. Comp Biochem Physiol B. 1976;55(2):161-6. doi: 10.1016\u002F0305-0491(76)90223-6. No abstract available.",[],{"nct_id":4,"conditions":87,"biomarkers":89},[88],"Obsessive Compulsive Disorder",[],{"nct_id":4,"found":91,"summary":92,"prompt_version":102},true,{"design":93,"status":94,"heading":95,"summary":96,"follow_up":97,"word_count":98,"commitments":99,"compensation":100,"drugs_mentioned":101},"This is an observational study aiming to enroll 500 participants. It is not testing a specific intervention.","completed","Understanding OCD Clinical Trial Participation","This study is looking to understand why people with Obsessive-Compulsive Disorder (OCD) join or don't join clinical trials, and what helps them complete a trial. It's an observational study, meaning researchers will collect information about your experiences rather than testing a new treatment. They hope to learn what factors, like your background or the trial's design, affect participation. This information could help make future OCD trials better for patients. The study aims to enroll 500 participants and is currently unclear on its recruitment status. You can join if you are 18 or older, have an OCD diagnosis, and are willing to follow the study's requirements.","The study measures how many participants enroll at 3 months and how many complete the trial at 12 months.",105,"You would need to comply with scheduled visits, treatment schedules, laboratory tests, and other study requirements. The study measures participation at 3 months and completion at 12 months.","Not stated in the trial record.",[],"v2"]